The stocks for both Swiss and Israeli biotechs were up over 20% after the companies signed a merger agreement.

Vertex is approaching two key PDUFA dates in January for new treatments in cystic fibrosis and pain respectively.

Nektar has signed a definitive agreement to divest its Huntsville facility and associated reagent supply business to ...

The EMA has accepted a MAA for Alvotech and Advanz Pharma’s AVT05, a proposed biosimilar to Johnson & Johnson’s (J&J) Simponi ...

Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them ...

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

Increasingly, injectable manufacturers recognise that to achieve maximum profitability, they need to focus on the value they ...

The first programme in the partnership involves the creation of an ‘early warning system’ for future pandemics. Credit: ...

Rosacea is thought to affect around 5% of the global population. Credit: Alona Siniehina / Shutterstock. The US’ Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi, the brand ...

Fiona Barry is the Editor-in-Chief of GlobalData PharmSource’s editorial content. She previously worked as an investigative ...